Jane W Newburger1, Lynn A Sleeper2, J William Gaynor3, Danielle Hollenbeck-Pringle4, Peter C Frommelt5, Jennifer S Li6,7,8, William T Mahle9, Ismee A Williams10, Andrew M Atz11, Kristin M Burns12, Shan Chen4, James Cnota13, Carolyn Dunbar-Masterson2, Nancy S Ghanayem5, Caren S Goldberg14, Jeffrey P Jacobs15, Alan B Lewis16, Seema Mital17, Christian Pizarro18, Aaron Eckhauser19, Paul Stark4, Richard G Ohye14. 1. Boston Children's Hospital and Harvard Medical School, MA (J.W.N., L.A.S., C.D.-M.). jane.newburger@cardio.chboston.org. 2. Boston Children's Hospital and Harvard Medical School, MA (J.W.N., L.A.S., C.D.-M.). 3. Children's Hospital of Philadelphia and University of Pennsylvania Medical School, Philadelphia (J.W.G.). 4. New England Research Institutes, Watertown, MA (D.H.-P., S.C., P.S.). 5. Children's Hospital of Wisconsin and Medical College of Wisconsin, Milwaukee (P.C.F., N.S.G.). 6. North Carolina Consortium, Duke University, Durham (J.S.L.). 7. East Carolina University, Greenville, NC (J.S.L.). 8. Wake Forest University, Winston-Salem, NC (J.S.L.). 9. Children's Healthcare of Atlanta and Emory University, GA (W.T.M.). 10. Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia College of Physicians and Surgeons, NY (I.A.W.). 11. Medical University of South Carolina, Charleston (A.M.A.). 12. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (KM.B.). 13. Cincinnati Children's Medical Center, OH (J.C.). 14. University of Michigan Medical School, Ann Arbor (C.S.G., R.G.O.). 15. Congenital Heart Institute of Florida, St. Petersburg (J.P.J.). 16. Children's Hospital Los Angeles, CA (A.B.L.). 17. Hospital for Sick Children, Toronto, Ontario, Canada (S.M.). 18. Nemours Cardiac Center, Wilmington, DE (C.P.). 19. Primary Children's Hospital and the University of Utah, Salt Lake City (A.E.).
Abstract
BACKGROUND: In the SVR trial (Single Ventricle Reconstruction), 1-year transplant-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock-Taussig shunt in patients with hypoplastic left heart and related syndromes. At 6 years, we compared transplant-free survival and other outcomes between the groups. METHODS: Medical history was collected annually using medical record review, telephone interviews, and the death index. The cohort included 549 patients randomized and treated in the SVR trial. RESULTS:Transplant-free survival for the RVPAS versus modified Blalock-Taussig shunt groups did not differ at 6 years (64% versus 59%, P=0.25) or with all available follow-up of 7.1±1.6 years (log-rank P=0.13). The RVPAS versus modified Blalock-Taussig shunt treatment effect had nonproportional hazards (P=0.009); the hazard ratio (HR) for death or transplant favored the RVPAS before stage II surgery (HR, 0.66; 95% confidence interval, 0.48-0.92). The effect of shunt type on death or transplant was not statistically significant between stage II to Fontan surgery (HR, 1.36; 95% confidence interval, 0.86-2.17; P=0.17) or after the Fontan procedure (HR, 0.76; 95% confidence interval, 0.33-1.74; P=0.52). By 6 years, patients with RVPAS had a higher incidence of catheter interventions (0.38 versus 0.23/patient-year, P<0.001), primarily because of more interventions between the stage II and Fontan procedures (HR, 1.72; 95% confidence interval, 1.00-3.03). Complications did not differ by shunt type; by 6 years, 1 in 5 patients had had a thrombotic event, and 1 in 6 had had seizures. CONCLUSIONS: By 6 years, the hazards of death or transplant and catheter interventions were not different between the RVPAS versus modified Blalock-Taussig shunt groups. Children assigned to the RVPAS group had 5% higher transplant-free survival, but the difference did not reach statistical significance, and they required more catheter interventions. Both treatment groups have accrued important complications. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00115934.
RCT Entities:
BACKGROUND: In the SVR trial (Single Ventricle Reconstruction), 1-year transplant-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock-Taussig shunt in patients with hypoplastic left heart and related syndromes. At 6 years, we compared transplant-free survival and other outcomes between the groups. METHODS: Medical history was collected annually using medical record review, telephone interviews, and the death index. The cohort included 549 patients randomized and treated in the SVR trial. RESULTS: Transplant-free survival for the RVPAS versus modified Blalock-Taussig shunt groups did not differ at 6 years (64% versus 59%, P=0.25) or with all available follow-up of 7.1±1.6 years (log-rank P=0.13). The RVPAS versus modified Blalock-Taussig shunt treatment effect had nonproportional hazards (P=0.009); the hazard ratio (HR) for death or transplant favored the RVPAS before stage II surgery (HR, 0.66; 95% confidence interval, 0.48-0.92). The effect of shunt type on death or transplant was not statistically significant between stage II to Fontan surgery (HR, 1.36; 95% confidence interval, 0.86-2.17; P=0.17) or after the Fontan procedure (HR, 0.76; 95% confidence interval, 0.33-1.74; P=0.52). By 6 years, patients with RVPAS had a higher incidence of catheter interventions (0.38 versus 0.23/patient-year, P<0.001), primarily because of more interventions between the stage II and Fontan procedures (HR, 1.72; 95% confidence interval, 1.00-3.03). Complications did not differ by shunt type; by 6 years, 1 in 5 patients had had a thrombotic event, and 1 in 6 had had seizures. CONCLUSIONS: By 6 years, the hazards of death or transplant and catheter interventions were not different between the RVPAS versus modified Blalock-Taussig shunt groups. Children assigned to the RVPAS group had 5% higher transplant-free survival, but the difference did not reach statistical significance, and they required more catheter interventions. Both treatment groups have accrued important complications. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00115934.
Authors: N H Atallah-Yunes; R E Kavey; E L Bove; F C Smith; D A Kveselis; C J Byrum; W E Gaum Journal: Circulation Date: 1996-11-01 Impact factor: 29.690
Authors: Lindsay S Rogers; Andrew C Glatz; Chitra Ravishankar; Thomas L Spray; Susan C Nicolson; Jack Rychik; Christina Hayden Rush; J William Gaynor; David J Goldberg Journal: J Am Coll Cardiol Date: 2012-07-18 Impact factor: 24.094
Authors: Elizabeth A Stephenson; Minmin Lu; Charles I Berul; Susan P Etheridge; Salim F Idriss; Renee Margossian; John H Reed; Ashwin Prakash; Lynn A Sleeper; Victoria L Vetter; Andrew D Blaufox Journal: J Am Coll Cardiol Date: 2010-09-07 Impact factor: 24.094
Authors: Richard G Ohye; J William Gaynor; Nancy S Ghanayem; Caren S Goldberg; Peter C Laussen; Peter C Frommelt; Jane W Newburger; Gail D Pearson; Sarah Tabbutt; Gil Wernovsky; Lisa M Wruck; Andrew M Atz; Steve D Colan; James Jaggers; Brian W McCrindle; Ashwin Prakash; Michael D Puchalski; Lynn A Sleeper; Mario P Stylianou; Lynn Mahony Journal: J Thorac Cardiovasc Surg Date: 2008-05-19 Impact factor: 5.209
Authors: Richard G Ohye; Julie V Schonbeck; Pirooz Eghtesady; Peter C Laussen; Christian Pizarro; Peter Shrader; Deborah U Frank; Eric M Graham; Kevin D Hill; Jeffrey P Jacobs; Kirk R Kanter; Joel A Kirsh; Linda M Lambert; Alan B Lewis; Chitra Ravishankar; James S Tweddell; Ismee A Williams; Gail D Pearson Journal: J Thorac Cardiovasc Surg Date: 2012-08-15 Impact factor: 5.209
Authors: Alexander R Opotowsky; Fernando R Baraona; Finnian R Mc Causland; Brittani Loukas; Elizabeth Landzberg; Michael J Landzberg; Venkata Sabbisetti; Sushrut S Waikar Journal: Heart Date: 2016-09-26 Impact factor: 5.994
Authors: Katie M Moynihan; Jennifer M Snaman; Erica C Kaye; Wynne E Morrison; Aaron G DeWitt; Loren D Sacks; Jess L Thompson; Jennifer M Hwang; Valerie Bailey; Deborah A Lafond; Joanne Wolfe; Elizabeth D Blume Journal: Pediatrics Date: 2019-08 Impact factor: 7.124
Authors: Thomas A Miller; Nancy S Ghanayem; Jane W Newburger; Brian W McCrindle; Chenwei Hu; Aaron G DeWitt; James F Cnota; Felicia L Tractenberg; Victoria L Pemberton; Michael J Wolf; Jodie K Votava-Smith; Carlen G Fifer; Linda M Lambert; Amee Shah; Eric M Graham; Christian Pizarro; Jeffrey P Jacobs; Stephen G Miller; L LuAnn Minich Journal: Pediatrics Date: 2019-04-12 Impact factor: 7.124
Authors: Sarah S Pickard; John B Wong; Emily M Bucholz; Jane W Newburger; Wayne Tworetzky; Terra Lafranchi; Carol B Benson; Louise E Wilkins-Haug; Diego Porras; Ryan Callahan; Kevin G Friedman Journal: Circ Cardiovasc Qual Outcomes Date: 2020-04-07
Authors: Peter C Frommelt; Chenwei Hu; Felicia Trachtenberg; Jeanne Marie Baffa; Richard J Boruta; Shahryar Chowdhury; James F Cnota; Andreea Dragulescu; Jami C Levine; Jimmy Lu; Laura Mercer-Rosa; Thomas A Miller; Amee Shah; Timothy C Slesnick; Gary Stapleton; Jessica Stelter; Pierre Wong; Jane W Newburger Journal: Circ Cardiovasc Imaging Date: 2019-02 Impact factor: 7.792
Authors: Caren S Goldberg; Chenwei Hu; Cheryl Brosig; J William Gaynor; William T Mahle; Thomas Miller; Kathleen A Mussatto; Renee Sananes; Karen Uzark; Felicia Trachtenberg; Christian Pizarro; Victoria L Pemberton; Alan B Lewis; Jennifer S Li; Jeffrey P Jacobs; James Cnota; Andrew M Atz; Wyman W Lai; David Bellinger; Jane W Newburger Journal: Pediatrics Date: 2019-10-18 Impact factor: 7.124
Authors: Aaron W Eckhauser; Maria I Van Rompay; Chitra Ravishankar; Jane W Newburger; S Ram Kumar; Christian Pizarro; Nancy Ghanayem; Felicia L Trachtenberg; Kristin M Burns; Garick D Hill; Andrew M Atz; Michelle S Hamstra; Mjaye Mazwi; Patsy Park; Marc E Richmond; Michael Wolf; Jeffrey D Zampi; Jeffrey P Jacobs; L LuAnn Minich Journal: Cardiol Young Date: 2019-11-26 Impact factor: 1.093
Authors: Masamichi Ono; Takashi Kido; Marie Wallner; Melchior Burri; Julia Lemmer; Peter Ewert; Martina Strbad; Julie Cleuziou; Alfred Hager; Jürgen Hörer Journal: Interact Cardiovasc Thorac Surg Date: 2021-07-26